The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial

Menter, Alan; Augustin, Matthias; Signorovitch, James; Yu, Andrew P.; Wu, Eric Q.; Gupta, Shiraz R.; Bao, Yanjun; Mulani, Parvez

doi:10.1016/j.jaad.2009.07.022

Cited by 162 publications

(169 citation statements)

References 42 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…Ustekinumab reduced depression 55%; 27% and 12% of patients reported depression before and after treatment, respectively [25]. Adalimumab reduced depression 18.5% [26]. Apremilast was associated with a small risk of depression in psoriasis patients (1.3% versus 0.4% in placebo) [27].…”

Section: Impact Of Treating Psoriasis On Depressionmentioning

confidence: 99%

Impact and management of depression in psoriasis patients

Korman

Hill

Alikhan

et al. 2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Section: Impact Of Treating Psoriasis On Depressionmentioning

confidence: 99%

Impact and management of depression in psoriasis patients

Korman

Hill

Alikhan

et al. 2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

“…Indeed, peripheral inflammatory conditions like rheumatoid arthritis (RA) and psoriasis that show high levels of circulating TNF-a are associated with psychiatric symptoms, such as cognitive decline, anxiety, and depression (Bassukas et al, 2008;Chandarana et al, 1987;Menter et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Effects of Centrally Administered Etanercept on Behavior, Microglia, and Astrocytes in Mice Following a Peripheral Immune Challenge

Camara

Corrigan

Jaehne

et al. 2014

Neuropsychopharmacol

View full text Add to dashboard Cite

“…Meta-analysis of RCTs of anti-cytokine drug vs placebo Meta-analysis of seven randomised, double-blind, placebocontrolled trials, 20,26,27,35,[45][46][47] involving 1309 subjects treated with anti-cytokine drugs and 1061 subjects treated with placebo, showed significant improvement in depressive symptoms with anti-cytokine treatment compared to placebo; SMD = 0.40 (95% CI, 0.22-0.59) (Figure 2a). There was evidence of significant heterogeneity among studies (P o 0.001; I 2 = 73%).…”

Section: Resultsmentioning

confidence: 99%

Antidepressant activity of anti-cytokine treatment: A systematic review and meta- analysis of clinical trials of chronic inflammatory conditions

Kappelmann

Lewis

Dantzer

et al. 2017

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Inflammatory cytokines are commonly elevated in acute depression and are associated with resistance to monoaminergic treatment. To examine the potential role of cytokines in the pathogenesis and treatment of depression, we carried out a systematic review and meta-analysis of antidepressant activity of anti-cytokine treatment using clinical trials of chronic inflammatory conditions where depressive symptoms were measured as a secondary outcome. Systematic search of the PubMed, EMBASE, PsycINFO and Cochrane databases, search of reference lists and conference abstracts, followed by study selection process yielded 20 clinical trials. Random effect meta-analysis of seven randomised controlled trials (RCTs) involving 2370 participants showed a significant antidepressant effect of anti-cytokine treatment compared with placebo (standardised mean difference (SMD) = 0.40, 95% confidence interval (CI), 0.22-0.59). Anti-tumour necrosis factor drugs were most commonly studied (five RCTs); SMD = 0.33 (95% CI; 0.06-0.60). Separate meta-analyses of two RCTs of adjunctive treatment with anti-cytokine therapy and eight nonrandomised and/or non-placebo studies yielded similar small-to-medium effect estimates favouring anti-cytokine therapy; SMD = 0.19 (95% CI, 0.00-0.37) and 0.51 (95% CI, 0.34-0.67), respectively. Adalimumab, etanercept, infliximab and tocilizumab all showed statistically significant improvements in depressive symptoms. Meta-regression exploring predictors of response found that the antidepressant effect was associated with baseline symptom severity (P = 0.018) but not with improvement in primary physical illness, sex, age or study duration. The findings indicate a potentially causal role for cytokines in depression and that cytokine modulators may be novel drugs for depression in chronically inflamed subjects. The field now requires RCTs of cytokine modulators using depression as the primary outcome in subjects with high inflammation who are free of other physical illnesses.

show abstract

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial

Cited by 162 publications

References 42 publications

Impact and management of depression in psoriasis patients

Impact and management of depression in psoriasis patients

Effects of Centrally Administered Etanercept on Behavior, Microglia, and Astrocytes in Mice Following a Peripheral Immune Challenge

Antidepressant activity of anti-cytokine treatment: A systematic review and meta- analysis of clinical trials of chronic inflammatory conditions

Contact Info

Product

Resources

About